

Vital Images Inc. (NSDQ:VTAL) and iCAD Inc. (NSDQ:ICAD) announced a strategic partnership to improve cancer identification imaging, the companies announced today.
With the agreement, iCAD’s VeraLook device, which produces three-dimensional images of the colon to assist physicians in detecting polyps and other suspicious tissue that can be an early sign of cancer, is available as part of Vital Images’ products worldwide.
"The vast majority of colorectal cancer deaths are preventable with early screening, and CT Colonography has the potential to eliminate many of the traditional barriers to routine colorectal screening," said Ken Ferry, president & CEO of iCAD.
Nashua, N.H.-based iCAD’s VeraLook won FDA 510(k) clearance in August 2010.
The details of the deal were not made public in the release.
Vital Images closed its $273 million acquisition by Toshiba Medical Systems Corp. earlier this month.